Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AN2 Therapeutics, Inc. - Common Stock
(NQ:
ANTX
)
2.560
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
2.560
Bid (Size)
2.480 (1)
Ask (Size)
2.820 (11)
Prev. Close
2.560
Today's Range
2.560 - 2.560
52wk Range
1.910 - 22.22
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
12 Health Care Stocks Moving In Friday's After-Market Session
June 14, 2024
Via
Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024
May 14, 2024
ANTX stock results show that AN2 Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
-87.12%
-87.12%
1 Month
+20.19%
+20.19%
3 Month
+6.67%
+6.67%
6 Month
-86.82%
-86.82%
1 Year
-68.47%
-68.47%
More News
Read More
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
May 14, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
April 04, 2024
Via
Benzinga
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023
March 28, 2024
Via
InvestorPlace
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
March 28, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
February 13, 2024
Via
Benzinga
Nasdaq Edges Lower; ContextLogic Shares Surge
February 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 12, 2024
Via
Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Mixed; Trimble Issues Weak Outlook
February 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today?
February 12, 2024
Via
Benzinga
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session
February 12, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 12, 2024
Via
Benzinga
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
February 12, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
January 30, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 09, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 06, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 18, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
October 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
September 13, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Top 5 Health Care Stocks That May Fall Off A Cliff
September 06, 2023
Via
Benzinga
$16M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
August 23, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
